Last reviewed · How we verify

NCT06867900

Unexplained Recurrent Pregnancy Loss: New Therapeutic Perspectives

Active, enrolled NA Last updated 10 March 2025
What this trial tests

NA trial testing Bifidobacterium Longum ES1 in Miscarriage, Recurrent in 22 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2021
Primary endpoint
5 July 2023
6 July 2025

Quick facts

Lead sponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment22
Start date1 January 2021
Primary completion5 July 2023
Estimated completion6 July 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, female only, with Miscarriage, Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of gut permeability and endometrial inflammasome NLRP3 in women with unexplaid recurrent pregnancy loss before-after administration of Bifidobacteriumlongum ES1.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Miscarriage, Recurrent

Currently open trials in the same condition.

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06867900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing